Quintrio
Home

MEDICINAL CHEMICALS & BOTANICAL PRODUCTS

Cronos Group Inc. Common Share

CRON

Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.

Last trade $3.21
Day change -$0.06 (-1.83%)
Day range $3.20 – $3.29
Volume 553,902
Market cap $1.20B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.2B
Price / earnings
20.72×
Price / book
1.12×
Price / sales
3.93×
EV / sales
2.58×
EV / EBITDA
29.47×

Profitability

Earnings per share
$0.16
Return on assets
4.83%
Return on equity
5.39%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
12.71×
Quick ratio
11.91×
Cash ratio
6.08×

Cash flow

Price / cash flow
14.78×
Price / free cash flow
18.33×
Free cash flow
$65.38M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CRON, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$83.9M$70.6M$58.97M$91.31M$48.83M$44.25M$41.9M$74.51M
Cost of revenue$29.53M$24.17M$26.06M$27.69M$17.5M$18.87M$18.53M$18.79M
Gross profit$54.38M$46.43M$32.91M$63.62M$31.33M$25.39M$23.37M$55.72M
Selling, general and administrative$21.45M$19.15M$18.66M$26.5M$16.89M$17.26M$15.96M$27.19M
Research and development$1.34M$1.22M$1.41M$1.38M$1.35M$929K$793K$1.03M
Total operating expenses$45.35M$39.03M$34.74M$71.12M$31.83M$30.71M$27.44M$92.74M
Operating income$9.03M$7.4M-$1.83M-$7.5M-$503K-$5.32M-$4.07M-$37.02M
Interest expense$0$8.82M$8.85M$0$0$9M$9.67M$0
Income before taxes$18.72M$35.71M$18.14M-$12.39M$27.01M-$39.01M$7.27M$45.95M
Income taxes$898K$51K$2.43M-$11.9M-$1.32M-$525K-$455K$2M
Net income$17.83M$35.66M$15.71M-$491K$28.32M-$38.48M$7.72M$43.94M
Net income attributable to common shareholders$13.8M$32.09M$13.75M-$1.82M$25.96M-$39.71M$6.12M$43.73M
EBITDA$15.49M$11.47M$2.38M-$2.64M$3.78M-$268K-$677K-$8.84M
Basic earnings per share$0.04$0.09$0.04$0.00$0.07-$0.10$0.02$0.11
Diluted earnings per share$0.04$0.09$0.04$0.00$0.07-$0.10$0.02$0.11

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Duke Robotics Announces Expansion of IC Drone Platform into Greece Through Strategic Collaboration with CRONOS

Duke Robotics Corp. (Nasdaq: DUKR) has entered into a strategic collaboration agreement with CRONOS, a Greek security and technology services company, to commercialize and operate its Insulator Cleaning Drone (IC Drone) technology in Greece. The three-year agreement leverages CRONOS's established presence in Greece's critical infrastructure and energy sectors, with Duke Robotics providing its proprietary IC Drone technology while sharing profits from joint projects, with Duke receiving the majority share. The parties have already identified potential large-scale projects with significant revenue potential.

The Motley Fool

Which of These 5 Cannabis Stocks Has the Strongest Balance Sheet?

An analysis of five major cannabis stocks reveals significant differences in financial health. Cronos Group leads with approximately $841 million in cash and no significant debt, followed closely by SNDL, which is debt-free with positive free cash flow. Tilray and Canopy Growth continue to struggle with debt and negative cash flow despite some revenue growth, while Aurora Cannabis has a smaller liquidity cushion. A strong balance sheet provides financial flexibility but doesn't guarantee profitability or shareholder returns.

Zacks Investment Research

Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates

Zevra Therapeutics reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.14, with revenues of $37.76 million exceeding expectations by 2.77%. The company has outperformed market estimates in four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Cronos Group is expected to report Q3 results on November 5, with projected earnings of $0.03 per share, down 57.1% year-over-year, though revenues are expected to grow 30.6%.

Zacks Investment Research

Cronos (CRON) Upgraded to Strong Buy: Here's What You Should Know

Cronos Group (CRON) received an upgrade to Zacks Rank #1 (Strong Buy) based on upward revisions in earnings estimates. The cannabis company has seen analysts steadily raise estimates over the past three months, with consensus estimates increasing 200%. The upgrade positions CRON in the top 5% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.

GlobeNewswire Inc.

Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company

Cronos Group has completed its acquisition of CanAdelaar B.V., the largest cannabis company in the Netherlands' adult-use cannabis pilot program (Wietexperiment), for a base purchase price of €57.5 million plus contingent cash earnouts. The acquisition establishes Cronos as the market leader in Europe's largest adult-use cannabis market and enables the company to execute its borderless product strategy in the Netherlands with CanAdelaar's proven operational track record and leading market share.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.